U.S., Dec. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07261592) titled 'Entinostat & Chemotherapy for Locally Advanced or Metastatic Bladder Cancer' on Nov. 22.
Brief Summary: This single-center single-arm, open-label prospective clinical trial aimed to evaluate the efficacy and safety of entinostat combined with chemotherapy as second-line therapy for unresectable locally advanced or metastatic bladder cancer.
Study Start Date: Dec. 01
Study Type: INTERVENTIONAL
Condition:
Bladder Cancer
Histone Deacetylase Inhibitor
Entinostat
Chemotherapy
Intervention:
DRUG: Entinostat
Take entinostat 5mg orally once weekly (at least 1 hour before meal and 2 hours after meal).
DRUG: Chemotherapy
Gisantinib an...